yes will be helpful if they have anything new- but that will already be out in PR's to come before a paper- doubt strongly they would hold back positive news given current sorry share price
they have already stood up at ASCO and presented data about Kevetrin on a couple of occasions for their peers
Strongly doubt pahse 1 data will go in a high impact journal- UNLESS there is new compelling data
No high impact journal that would publish what we have been told so far- hey everybody, a drug acting on p53 has proven to be safe
The methods and materials have been out for many moons already